Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia (ITIC2)
ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
Sponsor: Krankenhaus Barmherzige Schwestern Linz
Terminated
poor recruitment
Other terminated trials from Krankenhaus Barmherzige Schwestern Linz
See all terminations from Krankenhaus Barmherzige Schwestern Linz
Other Cervical Intraepithelial Neoplasia trials with similar outcome
This PHASE3 trial investigates Cervical Intraepithelial Neoplasia and is currently terminated or withdrawn. Krankenhaus Barmherzige Schwestern Linz leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Krankenhaus Barmherzige Schwestern Linz
- Medical University Innsbruck
- Medical University of Graz
- Medical University of Vienna
- Salzburger Landeskliniken
For direct contact, visit the study record on ClinicalTrials.gov .